Susceptibility to infectious diseases in obesity: an endocrine, translational, sociological evaluation
NCT ID NCT05975541
First seen Sep 10, 2026 · Last updated Sep 10, 2026
Summary
The role of intestinal microbiota is becoming ever more important in the context of obesity, type II diabetes (T2D), and infectious disorders as represented by the emerging discipline "therapeutic microbiology". The gut microbiota is strictly interconnected with obesity and T2D playing also an important role in immune system regulation. Obesity and diabetes can lead to chronic inflammation, which results in the secretion of pro-inflammatory cytokines like IL-6, IL-1, and TNF-alpha, causing immune system alteration which predisposes patients with obesity and T2D to chronic infections. Therefore, the principal aim of the study is to investigate changes in gut microbiota composition between patients with chronic infections or not, so as to attribute to specific phyla the formation of the infections in these patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The population of interest for this study will be recruited by the endocrinology of the hospital "Maggiore della Carità" of Novara. The patients recruited will be equally divided into the two groups according to the presence or not of concurrent infections and will be adequately matched by age, sex, and characteristics in order to maintain a certain homogeneity of the study.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * age between 18-65 years * ability to understand the study protocol * obesity with BMI between 30-40 kg/m2 * affects by type II diabetes * presence/absence of chronic infections * the possibility of equality in the two groups (matched for sex, age, and therapies) Exclusion Criteria: * psychological conditions that reduced the ability the comprehension of the study protocol * subjects undergoing a diet-therapeutic regimen; * subjects with the possibility of developing diabetic foot in the successive months * patients with relapsing infections * pregnancy * bariatric surgery * oncological and hematological pathologies * Hypogonadism * severe immunodepression * vaccination in the last two weeks * Alcohol or drug abuse * antibiotic therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Maggiore della Carità Hospital
RECRUITINGNovara, Novara, 28100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A multicenter, randomized, Active-Controlled, Open-Label phase IIb study evaluating safety and tolerability of switching to zovaglutide injection after titration to 2.4 mg semaglutide injection (Wegovy®) in adults with obesity (HORIZON-SWITCH-SZ)
- Gonadotropin-releasing hormone agonist (GnRHa) plus letrozole in obese progestin-insensitive early-stage endometrial cancer patients with conservative treatment
- Safety and feasibility of the ENDOPLY system in humans: a pilot study
- Dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like Peptide-1 (GLP-1) receptor agonist in women with obesity for frozen embryo transfer (FET): pragmatic, multicenter, randomized controlled trial
- Effects of very low calorie ketogenic diet on microbiota, adipose tissue and immunitary regulation: pilot study on patients with metabolic syndrome
- Endoscopic band ligation for weight loss